Application No. 10/076,071 Amendment dated June 25, 2008 Reply to Office Action dated December 26, 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-530 (Canceled).

531. (Currently amended) A method of treating an angiogenic disease or condition in an animal comprising administering to the animal an amount of a metal-binding peptide which does not have a metal ion bound to it or of a physiologically-acceptable salt of the peptide, the amount of the peptide or salt which is administered to the animal being effective to inhibit angiogenesis, the sequence of the peptide being:

$$P_1 - P_2$$

wherein:

 P_1 is:

Xaa₁ Xaa₂ His or

Xaa₁ Xaa₂ His Xaa₃,

the P₁ portion of the peptide being linear;

Xaa₁ is the N-terminal amino acid of the peptide, the only substituents on the α -amino group of Xaa₁ are hydrogen, and Xaa₁ is glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, ornithine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, or α -hydroxymethylserine;

Xaa₂ is alanine, β -alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, ornithine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, or α-hydroxymethylserine;

Xaa₃ is glycine, alanine, valine, lysine, arginine, ornithine, aspartic acid, glutamic acid, asparagine, glutamine or tryptophan; and

 P_2 is an amino acid sequence which comprises the sequence of a metal $\underline{Cu(I)}$ binding site, and P_2 contains no more than 10 amino acids.

532. (Previously presented) The method of Claim 531 wherein:

Xaa₁ is glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, glutamic acid, lysine, hydroxylysine, histidine, arginine, or α -hydroxymethylserine, and

 Xaa_2 is alanine, valine, leucine, isoleucine, threonine, serine, asparagine, glutamine, cysteine, methionine, lysine, hydroxylysine, histidine, arginine, or α -hydroxymethylserine.

- 533. (Previously presented) The method of Claim 531 wherein Xaa_1 is aspartic acid, glutamic acid, arginine, threonine or α -hydroxymethylserine.
- 534. (Previously presented) The method of Claim 531 wherein Xaa_2 is alanine, valine, leucine, isoleucine, threonine, serine, asparagine, methionine, histidine or α -hydroxymethylserine.
 - 535. (Previously presented) The method of Claim 531 wherein Xaa₃ is lysine.
 - 536. (Previously presented) The method of Claim 531 wherein:

 Xaa_1 is aspartic acid, glutamic acid, arginine, lysine, threonine, serine or α -hydroxymethylserine,

 Xaa_2 is alanine, valine, leucine, isoleucine, threonine, serine, asparagine, methionine, histidine or α -hydroxymethylserine, and

Xaa₃, when present, is lysine.

- 537. (Previously presented) The method of Claim 536 wherein Xaa_1 is aspartic acid or glutamic acid and Xaa_2 is alanine, valine, leucine, isoleucine, threonine, serine or α -hydroxymethylserine.
- 538. (Previously presented) The method of Claim 537 wherein Xaa₂ is alanine, valine, leucine or isoleucine.
- 539. (Previously presented) The method of Claim 538 wherein P_1 is Asp Ala His or Asp Ala His Lys.
 - 540. (Previously presented) The method of Claim 539 wherein P_1 is Asp Ala His Lys.
- 541. (Previously presented) The method of Claim 536 wherein Xaa_1 is arginine, lysine, threonine, serine or α -hydroxymethylserine, and Xaa_2 is alanine, valine, leucine, isoleucine, threonine, serine or α -hydroxymethylserine.

Application No. 10/076,071 Amendment dated June 25, 2008 Reply to Office Action dated December 26, 2007

542. (Previously presented) The method of Claim 541 wherein P₁ is Thr Leu His, HMS HMS His or Arg Thr His.

543-550 (Canceled)

551. (Currently amended) The method of Claim $\frac{550}{531}$ wherein P_2 comprises one of the following sequences:

Met Xaa₄ Met,

Met Xaa₄ Xaa₄ Met,

Cys Cys,

Cys Xaa₄ Cys,

Cys Xaa₄ Xaa₄ Cys,

Met Xaa₄ Cys Xaa₄ Xaa₄ Cys,

Gly Met Xaa₄ Cys Xaa₄ Xaa₄ Cys [SEQ ID NO:7],

Gly Met Thr Cys Xaa₄ Xaa₄ Cys [SEQ ID NO:8],

Gly Met Thr Cys Ala Asn Cys [SEQ ID NO:9], or

γ-Glu Cys Gly.

552. (Previously presented) The method of Claim 551 wherein P₂ is Gly Met Thr Cys Ala Asn Cys [SEQ ID NO:9].

553-554. (Canceled)

555. (Previously presented) The method of Claim 531 wherein at least one of the amino acids of P_1 other than β -alanine or glycine, when present, is a D-amino acid.

556-557 (Canceled)

558. (Previously presented) The method of Claim 531 or 555 wherein at least one of the amino acids of P_2 other than β -alanine or glycine, when present, is a D-amino acid.

559. (Canceled)

560. (Previously presented) The method of Claim 531 wherein the terminal -COOH of P_1 - P_2 is substituted to produce -COR₂, wherein R_2 is -NH₂, -NHR₁, -N(R_1)₂, -OR₁, or -R₁, wherein R_1 is an alkyl, aryl or heteroaryl.

561-568. (Canceled)

- 569. (Previously presented) The method of Claim 531 wherein the angiogenic disease or condition is a neoplastic disease, a connective tissue disorder, psoriasis, an ocular angiogenic disease, a cardiovascular disease, a cerebral vascular disease, hemophiliac joints, an immune disorder, a benign tumor, hypertrophy, endometriosis, polyposis, or obesity.
- 570. (Previously presented) The method of Claim 569 wherein the angiogenic disease or condition is a neoplastic disease.
- 571. (Previously presented) The method of Claim 570 wherein the neoplastic disease is a tumor.
- 572. (Previously presented) The method of Claim 571 wherein the tumor is located in the bladder, brain, breast, kidney, liver, pancreas, lung, cervix, ovary, prostate, stomach, intestines, colon, rectum, or uterus.
- 573. (Previously presented) The method of Claim 570 wherein the neoplastic disease is tumor metastasis.
- 574. (Previously presented) The method of Claim 569 wherein the angiogenic disease or condition is psoriasis.
- 575. (Previously presented) The method of Claim 569 wherein the angiogenic disease or condition is an ocular angiogenic disease.
- 576. (Previously presented) The method of Claim 575 wherein the ocular angiogenic disease is macular degeneration.

577-580. (Canceled)

- 581. (Currently amended) The method of any one of Claims 550-552 Claim 551 wherein P₁ is Asp Ala His or Asp Ala His Lys.
 - 582. (New) The method of Claim 552 wherein P₁ is Asp Ala His or Asp Ala His Lys.